Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193805-21-000202
Filing Date
2021-02-12
Accepted
2021-02-12 12:31:55
Documents
1
Group Members
DEERFIELD MANAGEMENT COMPANY, L.P.DEERFIELD MGMT III, L.P.DEERFIELD MGMT, L.P.DEERFIELD PARTNERS, L.P.DEERFIELD PRIVATE DESIGN FUND III, L.P.DEERFIELD SPECIAL SITUATIONS FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 e620275_sc13ga-xeris.htm SC 13G/A 146075
  Complete submission text file 0001193805-21-000202.txt   147634
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Subject) CIK: 0001346302 (see all company filings)

EIN.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90534 | Film No.: 21624800
SIC: 2834 Pharmaceutical Preparations

Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SC 13G/A